4.6 Review

Discovery, development, and future application of senolytics: theories and predictions

Journal

FEBS JOURNAL
Volume 287, Issue 12, Pages 2418-2427

Publisher

WILEY
DOI: 10.1111/febs.15264

Keywords

dasatinib; fisetin; Geroscience Hypothesis; MAD cells; navitoclax; quercetin; SASP; SCAPs; senolytics

Funding

  1. NIA NIH HHS [R56 AG061414, P01 AG062413, R37 AG013925, R33 AG061456] Funding Source: Medline

Ask authors/readers for more resources

Senescent cells accumulate with aging and at etiological sites of multiple diseases, including those accounting for most morbidity, mortality, and health costs. Senescent cells do not replicate, can release factors that cause tissue dysfunction, and yet remain viable. The discovery of senolytic drugs, agents that selectively eliminate senescent cells, created a new route for alleviating age-related dysfunction and diseases. As anticipated for agents targeting fundamental aging mechanisms that are 'root cause' contributors to multiple disorders, potential applications of senolytics are protean. We review the discovery of senolytics, strategies for translation into clinical application, and promising early signals from clinical trials.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available